← Back to Search

Procedure

Ablative Therapy for Oligoprogressive Cancer (VALOROUS Trial)

N/A

Recruiting

Led By Xiao Zhao, MD

Research Sponsored by University of California, Davis

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Age ≥18 years at time of consent.

≤ 5 progressing or new metastatic lesions.

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 3 months from the first day of ablative local therapy

Awards & highlights

VALOROUS Trial Summary

This trial studies the effectiveness of adding localized treatments to systemic therapy for solid tumors that have not spread widely. The results will measure how long treatment lasts.

Who is the study for?

Adults over 18 with certain cancers (like breast, gynecological, head and neck, sarcomas) who have up to 5 new or worsening metastatic lesions. They must be on systemic therapy they can continue post-treatment and have seen benefits from it for at least 3 months. Not eligible if they have progressing brain tumors or health issues that rule out local therapies.Check my eligibility

What is being tested?

The VALOROUS trial is testing whether adding local ablative treatments (like radiation) to ongoing systemic cancer therapy helps control the disease better in patients whose cancer has started to progress again but only in a limited number of spots.See study design

What are the potential side effects?

While specific side effects are not listed here, generally, local ablative therapies like radiation may cause skin irritation, fatigue, mild pain or discomfort at the treatment site. The exact side effects depend on the area being treated.

VALOROUS Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 years old or older.

Select...

I have 5 or fewer new or growing cancer spots.

Select...

My cancer is confirmed to be in the urinary-genital area.

Select...

I have cancer in my head or neck.

VALOROUS Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 3 months from the first day of ablative local therapy

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~3 months from the first day of ablative local therapy

This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months from the first day of ablative local therapy for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Disease control

Secondary outcome measures

Grade ≥ 3 adverse events

Median overall survival

Time to treatment failure

VALOROUS Trial Design

1Treatment groups

Experimental Treatment

Group I: Ablative local therapyExperimental Treatment1 Intervention

Stereotactic ablative radiotherapy (SABR) or interventional radiology (IR) ablation therapy

0 / 4Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of California, DavisLead Sponsor

911 Previous Clinical Trials

4,709,269 Total Patients Enrolled

1 Trials studying Sarcoma

8 Patients Enrolled for Sarcoma

National Cancer Institute (NCI)NIH

13,669 Previous Clinical Trials

40,926,071 Total Patients Enrolled

454 Trials studying Sarcoma

229,955 Patients Enrolled for Sarcoma

Xiao Zhao, MDPrincipal InvestigatorUniversity of California, Davis

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there still openings for attendees in this research project?

"Affirmative. Information on clinicaltrials.gov confirms that the research project, which was initially published on October 5th 2023 is currently recruiting participants. Approximately 250 individuals need to be enrolled from 1 different medical facility."

Answered by AI

How many participants can the study accommodate in total?

"Yes, the evidence on clinicaltrials.gov implies that this research is presently enrolling volunteers. The trial was initially posted on October 5th 2023 and most recently updated on October 19th of the same year. Approximately 250 subjects must be recruited from 1 location."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Locally ablatiVe therApy in oLigO-pRogressive sOlid tUmorS (VALOROUS)

2023. "Locally ablatiVe therApy in oLigO-pRogressive sOlid tUmorS (VALOROUS)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06103669.

All > Sarcoma